Dalton Receives Notice of Award from NIDA of NIH to Fund Research
News Sep 06, 2013
Dalton Medicinal Chemistry has received notice of award from the National Institute On Drug Abuse (NIDA) to research and discover a novel series of compounds with the potential to treat drug abuse and alleviate pain.
This work will be supported by NIDA of the National Institutes of Health (NIH) under Award Number R21DA036251 which includes funding for the project.
Dalton Medicinal Chemistry will utilize their proprietary knowledge and expertise to design, synthesize and test several novel classes of compounds for these applications.
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It is exceptionally exciting to receive notice of this competitive award from National Institute On Drug Abuse (NIDA) which germinated from the creative insights of the talented scientists at Dalton. We are delighted to have the opportunity to initiate and conduct this important research.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019